CSChetan Pratap Singh

Chetan Pratap Singh

*This is an algorithmically generated author record based on publicly available information.

Chetan Pratap Singh has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Ankita Wal

    PSIT-Pranveer Singh Institute of Technology (Pharmacy), NH-19, Kanpur, Uttar Pradesh, 209305, India

    1 shared publication
  • Ankur Agrawal

    School of Pharmacy, Jai Institute of Pharmaceutical Sciences and Research, Gwalior, MP, India

    1 shared publication
  • Azhar Rasheed

    PSIT-Pranveer Singh Institute of Technology (Pharmacy), NH-19, Kanpur, Uttar Pradesh, 209305, India

    1 shared publication
  • Lalit Kumar Tyagi

    Department of Pharmacy, Lloyd Institute of Management and Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh, 201306, India

    1 shared publication
  • Namra Aziz

    PSIT-Pranveer Singh Institute of Technology (Pharmacy), NH-19, Kanpur, 209305, Uttar Pradesh, India

    1 shared publication
  • Pranay Wal

    PSIT-Pranveer Singh Institute of Technology (Pharmacy), Bhauti Kanpur, Uttar Pradesh, India

    1 shared publication

Latest Publications

  • Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders

    by Pranay Wal, Namra Aziz, Chetan Pratap Singh, Azhar Rasheed, Lalit Kumar Tyagi, Ankur Agrawal, Ankita Wal

    Cardiovascular disorders (CVD) are the primary cause of death worldwide. Multiple factors have been accepted to cause cardiovascular diseases; among them, smoking, physical inactivity, unhealthy eating habits, age, and family history are flag-bearers. Individuals at risk of developing CVD are suggested to make drastic habitual changes as the primary intervention to prevent CVD; however, over time, the disease is bound to worsen. This is when secondary interventions come into play, including antihypertensive, anti-lipidemic, anti-anginal, and inotropic drugs. These drugs usually undergo surgical intervention in patients with a much higher risk of heart failure. These therapeutic agents increase the survival rate, decrease the severity of symptoms and the discomfort that comes with them, and increase the overall quality of life. However, most individuals succumb to this disease. None of these treatments address the molecular mechanism of the disease and hence are unable to halt the pathological worsening of the disease. Gene therapy offers a more efficient, potent, and important novel approach to counter the disease, as it has the potential to permanently eradicate the disease from the patients and even in the upcoming generations. However, this therapy is associated with significant risks and ethical considerations that pose noteworthy resistance. In this review, we discuss various methods of gene therapy for cardiovascular disorders and address the ethical conundrum surrounding it.